Search
Xylose
go.drugbank.com/drugs/DB09419ApprovedWithdrawnD-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption. … Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood.
Iron protein succinylate
go.drugbank.com/drugs/DB11209ApprovedMixtures: PR Natal 430 ec, PR Natal 400 ecSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327] … [L24474] It is an agonist of the melanocortin 4 receptor.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalHowever, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect. … Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease.
Synonyms: N-(n-Butyl)deoxynojirimycin, N-ButylmoranolineDasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39190] Severe hypoglycemia is an acute, life-threatening medical condition resulting from a profound drop in blood glucose levels. … [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes
Pirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnin a concentration between 10-50%. … In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol.
Categories: Compounds used in a research, industrial, or household settingPotassium alum
go.drugbank.com/drugs/DB09087ApprovedWithdrawn[L1070] It is an inorganic salt, also called potassium aluminum sulfate with a formula of AlK(SO4)2 that is predominantly produced in the dodecahydrate form (AlK(SO4)2 * 12H2O). … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]
Products: Gingibraid W Alum Pot Sulf 0a 0.25mg/2.5cm, Gingibraid W Alum Pot Sulf 1a 0.35mg/2.5cmNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household settingCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.